Open Outbreak

Marburg virus disease

Also known as: Marburg, marburgvirus, MVD, Marburg haemorrhagic fever, Marburg hemorrhagic fever, Marburg virus, Ravn virus, Orthomarburgvirus marburgense

Marburg virus disease is a rare but severe illness caused by Marburg virus or the closely related Ravn virus. It belongs to the same virus family as Ebola and causes a similar illness. Fruit bats are the natural host. People can become infected after exposure in caves or mines containing these bats. The virus then spreads through direct contact with an infected person’s blood or other bodily fluids, or contaminated materials. Caregiving, healthcare work and funerals can create risks when protective measures are missing. Symptoms begin 2–21 days after infection, often with sudden fever, headache and muscle pain. Vomiting and diarrhoea can follow; severe illness can cause bleeding, shock and organ failure. WHO reports that death rates have varied greatly between outbreaks, with early care improving survival. The WHO sources retrieved for this page report no approved vaccine or antiviral treatment. Supportive treatment, rapid diagnosis, infection prevention and monitoring exposed people are central to controlling outbreaks. The latest WHO notice retrieved reports that Ethiopia’s first outbreak ended on 2026-01-26.

Key facts

TransmissionInitial infection is associated with exposure to infected fruit bats, including in caves or mines. Human-to-human spread occurs through direct contact with infected bodily fluids or contaminated materials, including during healthcare and burial practices. WHO states that people do not transmit the disease before symptoms.
Incubation2–21 days, according to WHO.
Case fatalityWHO reports an average around 50%, with 24–88% in past outbreaks. Early supportive care improves survival, but the retrieved sources do not provide separate general estimates with and without treatment. Rwanda’s 2024 outbreak had a reported case fatality ratio of 23%.
Reproduction numberunknown
VaccineNo approved vaccine according to the retrieved WHO sources; candidate vaccines are under investigation. Approval status on 2026-11-22 was not independently established.
TreatmentEarly intensive supportive care, including rehydration and treatment of specific symptoms, improves survival. The retrieved WHO sources report no approved antiviral treatment; candidate antibodies and antivirals are under investigation.
ReservoirRousettus aegyptiacus fruit bats are considered the natural host.
Endemic regionsReported outbreaks are concentrated in Africa, including Angola, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Ghana, Guinea, Kenya, Rwanda, South Africa, Tanzania and Uganda. The reservoir’s range may extend beyond places with recognized human outbreaks.

Transmission

Marburg usually enters the human population through exposure to infected fruit bats. WHO links initial infections to prolonged time in mines or caves inhabited by Rousettus bats. Once a person is infected, the virus can spread through blood or other bodily fluids entering broken skin or the moist surfaces of the eyes, nose or mouth. Contaminated bedding, clothing and medical equipment can also transmit infection. Healthcare workers and caregivers face particular risks when infection-control measures are missing. Funerals involving direct contact with a body can spread the virus. WHO states that people cannot transmit the disease before symptoms begin. Protective care and safe, dignified burials are therefore important parts of outbreak control.

Symptoms and severity

Symptoms begin 2–21 days after infection. Illness often starts suddenly with high fever, severe headache, marked tiredness and muscle pain. Watery diarrhoea, abdominal cramps, nausea and vomiting can follow. Some patients develop bleeding, confusion, shock or organ failure. Early symptoms resemble malaria and several other infections, so symptoms alone cannot confirm Marburg; laboratory testing is needed. WHO reports an average case fatality rate around 50%, with historical outbreaks ranging from 24% to 88%. These figures are not an individual prognosis, and outcomes differ between outbreaks. Rwanda reported 15 deaths among 66 confirmed cases in 2024, a fatality ratio of 23%. Early supportive care can improve survival.

Treatment and vaccines

Early intensive supportive care is the main established treatment described by WHO. This includes replacing lost fluids and treating specific symptoms. It can improve survival, so suspected illness after a relevant exposure needs prompt medical assessment rather than waiting for bleeding to appear. Patients also need care that protects staff, relatives and other patients from infected bodily fluids. The retrieved WHO fact sheet and the notice dated 2026-01-26 report no approved vaccine or antiviral treatment for Marburg virus disease. Candidate vaccines, antibody treatments and antivirals are being investigated. Experimental availability should not be confused with proven benefit or regulatory approval. These sources do not independently establish whether approval status changed by 2026-11-22.

Where it occurs

Recognized outbreaks have mainly occurred in Africa. WHO lists Angola, the Democratic Republic of the Congo, Equatorial Guinea, Ghana, Guinea, Kenya, Rwanda, South Africa, Tanzania and Uganda; Ethiopia reported its first confirmed outbreak in 2025. This list does not mean transmission is continuously occurring throughout those countries. The natural host is a fruit bat, and WHO notes that the virus’s geographic distribution may overlap with the bats’ range. Infections can also be detected outside Africa after travel or other exposure. The disease was first recognized in Germany and Serbia in 1967, in outbreaks associated with imported African green monkeys. WHO also describes infections in travellers who visited a bat-inhabited cave in Uganda in 2008.

Recent history

Open Outbreak’s supplied archive contains 16 Marburg event records. These are site records, not a count of distinct outbreaks: the returned archive includes repeated notices for Rwanda and separate Democratic Republic of the Congo entries. Rwanda’s 2024 outbreak ended on 2024-12-20, with 66 confirmed cases and 15 deaths. Tanzania declared its 2025 outbreak over on 2025-03-13; WHO reported two confirmed and eight probable cases, all fatal. Ethiopia’s first confirmed outbreak was declared on 2025-11-14 and ended on 2026-01-26. As of 2026-01-25, WHO reported 14 confirmed cases, including nine deaths, and five probable cases, all fatal. That is the latest WHO notice retrieved here, not proof that no later events occurred before 2026-11-22.

What to watch

Important warning signals include cases in previously unaffected areas, unexplained chains of infection, and infections among healthcare workers or caregivers. Human-to-human transmission is already established; the concern is spread that goes undetected or continues despite control measures. Delayed diagnosis and unsafe contact during care or funerals can allow further transmission. Monitoring exposed people, investigating alerts and finding cases early remain important even after an outbreak ends. WHO’s Ethiopia notice records an outbreak-end declaration after 42 days without a new confirmed case, while still noting a risk of re-emergence. Vaccine and treatment developments also matter: watch for reliable evidence of benefit, regulatory approval and practical access. The retrieved sources do not establish a current antiviral-resistance problem or an approved-vaccine supply shortage.

Updated